SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (10523)10/31/1997 4:40:00 PM
From: Andrew H  Read Replies (2) | Respond to of 32384
 
Thanks, Henry. Very clear and helpful explanation. Great that LGND has most of the receptors. That should be worth a small fortune to them over the next several years as more and more is learned about the nature of these receptors. No wonder everyone want to partner with LGND. Guess they have already proved the efficacy of their targeting ability. Droloxifene was produced in this way, correct?



To: Henry Niman who wrote (10523)10/31/1997 8:08:00 PM
From: lavalamp  Read Replies (3) | Respond to of 32384
 
Henry,

What kind of ratio is it for men vs. women for Alzheimer's disease?



To: Henry Niman who wrote (10523)10/31/1997 10:06:00 PM
From: squetch  Read Replies (1) | Respond to of 32384
 
>>As LGND learns about which binding
profiles are most interesting as well as which modifications are most useful, they can
come up with better drugs through targeted drug screening. << Would you at some point describe this process? 100K is a lot of compounds to go thru. No rush Henry just curious.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News